STAT

FEBRUARY 29, 2024

The outage caused by the Change Healthcare cyberattack could last weeks, a top UnitedHealth executive suggested in a Tuesday conference call with hospital cybersecurity officers, according to a recording obtained by STAT. UnitedHealth Group Chief Operating Officer Dirk McMahon said the company is setting up a loan program to help providers who can’t submit insurance claims while Change is offline.

Hospitals 363

Hospitals 363

PharmaVoice

FEBRUARY 29, 2024

Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

195

195

STAT

FEBRUARY 29, 2024

The new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome, new data from the Centers for Disease Control and Prevention and the Food and Drug Administration suggest. At a meeting Thursday of the Advisory Committee on Immunization Practices, vaccine safety experts from the two agencies presented data that showed what appears to be an elevated rate of GBS, as the condition is called, am

Vaccines 355

Vaccines Immunity Immunization 355

Pharmaceutical Technology

FEBRUARY 29, 2024

India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.

143

143

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

FEBRUARY 29, 2024

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions. Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials.

Pharmaceutical Companies 347

Pharmaceutical Companies Pharmaceutical Companies Drug Development 347

LifeProNow

FEBRUARY 29, 2024

February 28, 2024: “The U.S. Food and Drug Administration is announcing that grease-proofing materials containing per- and polyfluoroalkyl substances (PFAS) are no longer being sold for use in food packaging in the U.S. This means the major source of dietary exposure to PFAS from food packaging like fast-food wrappers, microwave popcorn bags, take-out paperboard containers and pet food bags is being eliminated.

Packaging 100

Packaging 100

pharmaphorum

FEBRUARY 29, 2024

Explore how innovation in healthcare can be scaled across hospitals and nations, driving transformation through research & development, biotech collaborations, and fostering start-ups in the industry.

Hospitals 119

Hospitals 119

STAT

FEBRUARY 29, 2024

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine? That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

Vaccines 333

Vaccines 333

The Pharmacist

FEBRUARY 29, 2024

Proposed changes to supervision and patient group directions (PGDs) will deliver increased access to care ‘for the patient’ and relieve pressures on the workforce, the vice president of the Association of Pharmacy Technicians UK (APTUK) has suggested. Nicola Stockmann addressed ‘fearmongering’ around proposed changes to supervision – which the government is accepting feedback on until […] The post APTUK: 'Enabling pharmacy technicians is about patient access' appeared first on Th

Pharmacy Technician 112

Pharmacy Technician 112

STAT

FEBRUARY 29, 2024

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline. The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed.

Drug Development 315

Drug Development 315

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Digital Pharmacist

FEBRUARY 29, 2024

Did you know March is National Nutrition Month ? National Nutrition Month is an annual campaign sponsored by the Academy of Nutrition and Dietetics and it’s a great opportunity for local pharmacies to educate their patients on the importance of good nutrition, healthy diets, and exercise. Springtime, March specifically, is an excellent time of year for you to start conversations with your patients about the various foods they’re eating and how they can enhance their diets to improve

Health and Personal Care Stores 111

Health and Personal Care Stores Diabetes 111

STAT

FEBRUARY 29, 2024

Biotech is awash in PIPEs. The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year. Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year.

314

314

Pharmafile

FEBRUARY 29, 2024

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The drug is a first-in-class oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) for the […] The post AstraZeneca’s Voydeya recommended for approval in EU by CHMP appeared first on Pharmafile.

110

110

STAT

FEBRUARY 29, 2024

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution. Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen , a maker of a hot category of oncology medicines called antibody-drug conjugates.

Drug Development 299

Drug Development 299

World Pharma News

FEBRUARY 29, 2024

Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease).

Immunity 103

Immunity Immunization Vaccines 103

STAT

FEBRUARY 29, 2024

Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb for $4 billion, has raised $173 million from a coalition of top biotech investors for her new company, BlossomHill Therapeutics. BlossomHill is preparing to start human clinical studies of potential medicines that could someday treat blood cancer and lung cancer. It announced Thursday that it has raised $100 million from firms including Colt Ventures, Cormorant Asset Management, and OrbiMed.

295

295

The Pharmacist

FEBRUARY 29, 2024

Community pharmacies should shift further into clinical service provision, with the dispensing of medication becoming an ‘increasingly automated’ side offering, NHS England’s primary care director has said. Dr Amanda Doyle shared her ambition for the sector in a panel discussion at the NHS Confederation’s primary care conference on Wednesday, explaining that Pharmacy First was the […] The post Clinical service is the future for community pharmacy, says NHS director appeared first on The Ph

Community Pharmacies 103

Community Pharmacies 103

STAT

FEBRUARY 29, 2024

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.  Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and pension fund Alaska Permanent Fund Corp.

Drug Development 283

Drug Development 283

Pharmaceutical Technology

FEBRUARY 29, 2024

LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.

105

105

STAT

FEBRUARY 29, 2024

Flu vaccine appears to be offering reasonable levels of protection this winter, with particularly strong levels in children, new data from the Centers for Disease Control and Prevention suggest. The vaccine effectiveness estimates, which showed unusually robust protection of children against influenza B viruses but more modest protection of people aged 65 and older against influenza A viruses, were presented Wednesday at a meeting of the CDC’s expert vaccine panel, the Advisory Committee

Vaccines 262

Vaccines Immunity Immunization 262

European Pharmaceutical Review

FEBRUARY 29, 2024

Eligible individuals in England and Wales can access the first licensed treatment for amyloid light-chain (AL) amyloidosis on the NHS. The National Institute for Health and Care Excellence (NICE) recommended DARZALEX ® (daratumumab) plus VELCADE ® (bortezomib), cyclophosphamide and dexamethasone (DVCd) as an option for people newly diagnosed with the systemic form of the disease.

Documentation 101

Documentation Pharmaceutical Companies Pharmaceutical Companies 101

STAT

FEBRUARY 29, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Operation Tweak the IRA commences Two proposals to weaken Medicare’s drug price negotiation program are getting a hearing before a House Energy & Commerce subcommittee today.

Drug Pricing 228

Drug Pricing 228

pharmaphorum

FEBRUARY 29, 2024

It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats. On today’s podcast, host Jonah Comstock is joined by Cody Powers, principal of portfolio and business development at ZS Associates, to discuss those trends and predictions and how they’re shaking out so far.

100

100

STAT

FEBRUARY 29, 2024

Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea.

215

215

Pharma Times

FEBRUARY 29, 2024

Aphasia is a language disorder caused by some form of brain damage, including stroke

133

133

STAT

FEBRUARY 29, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an explanation of the latest trend in biotech financing, a big idea in oncology, and Novo Nordisk’s plans to make Wegovy obsolete.

Drug Pricing 198

Drug Pricing Drug Development Vaccines 198

pharmaphorum

FEBRUARY 29, 2024

Explore the impact of the Inflation Reduction Act (IRA) on drug prices and negotiations within the life sciences industry, as it stands on the threshold of change. Gain insights into the potential outcomes and implications of this legislation.

Drug Pricing 95

Drug Pricing 95

STAT

FEBRUARY 29, 2024

Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners, one of the drug industry’s largest and most active investment firms, and also outside of work — those who know her say Burow is a deadly shot with a pistol. Burow is a managing director at ARCH, where she has been influential in building bold and well-capitalized startups.

196

196

The Pharmacist

FEBRUARY 29, 2024

GP referrals to Pharmacy First have led to 8,400 consultations so far, Community Pharmacy North East London chief executive Shilpa Shah has said this week. And she revealed that a scheme to supply over-the-counter medicines free of charge to low income people in the area has now been approved. Speaking to delegates at the 2024 […] The post More than 8,000 Pharmacy First consultations in North East London so far appeared first on The Pharmacist.

Community Pharmacies 94

Community Pharmacies 94

STAT

FEBRUARY 29, 2024

Top of the morning to you, and a fine one it is. Cold winds and overcast skies will not deter us from celebrating another brand new day here on the Pharmalot campus, where the official mascots are hunting for creatures and a parade of driving machines is passing near by. As for us, we are engaged in the usual ritual — brewing cups of stimulation.

171

171

pharmaphorum

FEBRUARY 29, 2024

On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies.

96

96

Express Pharma

FEBRUARY 29, 2024

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently recommended the refusal of the marketing authorisation for Nezglyal (leriglitazone). Nezglyal is a novel orally bioavailable and selective peroxisome proliferator-activated receptor (PPAR) gamma agonist that is intended for the treatment of cerebral adrenoleukodystrophy (cALD).

90

90

Pharmaceutical Technology

FEBRUARY 29, 2024

Amyotrophic lateral sclerosis (ALS) is a swiftly advancing, fatal neurodegenerative condition marked by muscle weakness, atrophy, and spasticity.

98

98

Express Pharma

FEBRUARY 29, 2024

Suven Pharmaceuticals and Cohance Lifesciences announced a proposed scheme of amalgamation for the merger of Cohance with Suven. The merged entity is expected to be a leading integrated CDMO players in India with an expanded capacity to ~2,650 kL and a broadened customer base. Cohance is a CDMO and merchant API platform with strong capabilities in select low-mid volume molecules and its antibody drug conjugates (ADC) platform.

88

88

pharmaphorum

FEBRUARY 29, 2024

Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.

87

87